$1.67
5.70% yesterday
Nasdaq, Sep 03, 10:13 pm CET
ISIN
US09074F2074
Symbol
BIVI

BioVie Inc Stock price

$1.67
-4.33 72.17% 1M
-10.13 85.85% 6M
-18.33 91.65% YTD
-25.03 93.75% 1Y
-279.33 99.41% 3Y
-1,993.33 99.92% 5Y
-1,498.33 99.89% 10Y
-3,748.33 99.96% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.09 5.70%
ISIN
US09074F2074
Symbol
BIVI
Industry

Key metrics

Basic
Market capitalization
$12.6m
Enterprise Value
$-5.0m
Net debt
positive
Cash
$17.5m
Shares outstanding
1.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.3
P/B
0.7
Financial Health
Equity Ratio
88.2%
Return on Equity
-94.2%
ROCE
-91.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-17.4m | -
EBIT
$-17.6m | $-22.1m
Net Income
$-17.9m | $-1.2m
Free Cash Flow
$-19.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
45.6% | -
EBIT
45.3% | -25.7%
Net Income
45.7% | 93.5%
Free Cash Flow
32.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-9.6
FCF per Share
$-10.0
Short interest
2.2%
Employees
14
Rev per Employee
$0.0
Show more

Is BioVie Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

BioVie Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a BioVie Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a BioVie Inc forecast:

Buy
86%
Hold
14%

Financial data from BioVie Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.10 8.10
8% 8%
-
- Research and Development Expense 9.26 9.26
60% 60%
-
-17 -17
46% 46%
-
- Depreciation and Amortization 0.23 0.23
4% 4%
-
EBIT (Operating Income) EBIT -18 -18
45% 45%
-
Net Profit -18 -18
46% 46%
-

In millions USD.

Don't miss a Thing! We will send you all news about BioVie Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioVie Inc Stock News

Neutral
GlobeNewsWire
21 days ago
ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S.
Neutral
GlobeNewsWire
27 days ago
CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritten public offering of 6,000,000 units, with each unit con...
Neutral
GlobeNewsWire
about one month ago
Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases of aging Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases of aging
More BioVie Inc News

Company Profile

BioVie, Inc. is a development stage biopharmaceutical company, which discovers, develops, and commercializes drug therapies for liver disease. It focuses on BIV201 which treats ascites due to chronic liver cirrhosis. The company was founded on April 10, 2013 and is headquartered in Santa Monica, CA.

Head office United States
CEO Cuong Do
Employees 14
Founded 2013
Website www.bioviepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today